Delta-Fly Pharma, Inc.
Research Delta-Fly Pharma, Inc. (4598.T) on Bullrun: market cap JPY 1.19B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4598.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 1.19B
- Financial periodFY2026
- RevenueJPY 0
- Net income-JPY 1.63B
- Free cash flow-JPY 1.56B
Valuation Snapshot
latest market cap is JPY 1.19B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 0 | -JPY 1.63B | -JPY 1.56B | n/a | n/a | JPY 145.45M | n/a | JPY 33.98M |
| FY2025 | JPY 0 | -JPY 1.72B | -JPY 1.83B | n/a | -195.58 | JPY 338.83M | n/a | JPY 277.80M |
| FY2024 | JPY 0 | -JPY 1.43B | -JPY 1.28B | n/a | -198.78 | JPY 1.42B | n/a | JPY 1.23B |
| FY2023 | JPY 0 | -JPY 1.33B | -JPY 1.30B | n/a | -234.51 | JPY 844.34M | n/a | JPY 791.20M |
| FY2022 | n/a | n/a | n/a | n/a | -178.58 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 1.19B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase II/III clinical trials for the treatment of solid cancer; DFP-11207, which in phase I/II clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Delta-Fly Pharma, Inc.'s market cap?
Delta-Fly Pharma, Inc.'s market capitalization is JPY 1.19B.
What does Delta-Fly Pharma, Inc. do?
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase II/III clinical trials for the treatment of solid cancer; DFP-11207, which in phase I/II clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, to treat gastric/ovarian cancer.